Accueil › Cancer du poumon non à petites cellules › Texas › Tyler
Essais cliniques pour Cancer du poumon non à petites cellules à Tyler, TX
20 études pour Cancer du poumon non à petites cellules recherchent des participants dans et autour de Tyler (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Recrutement en coursPhase 3
- The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148), Tyler
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Recrutement en coursPhase 1
- Exelixis Clinical Site #70, Tyler
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Recrutement en coursPhase 1/2
- Research Site, Tyler
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Recrutement en coursPhase 3
- Texas Oncology - Northeast Texas, Tyler
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Recrutement en coursPhase 3
- Texas Oncology-Northeast Texas, Tyler
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- Texas Oncology - Northeast Texas, Tyler
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Recrutement en coursPhase 2
- The University of Texas Health Science Center at Tyler, Tyler
- Texas Oncology - Northeast, Tyler
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Recrutement en coursPhase 3
- The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center, Tyler
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Recrutement en coursPhase 2
- Texas Oncology - Northeast Texas /ID# 272000, Tyler
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Recrutement en coursPhase 3
- Texas Oncology - Northeast Texas, Tyler
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Recrutement en coursPhase 3
- Clinical Study Site, Tyler
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Recrutement en coursPhase 2/3
- Local Institution - 007-890-A, Tyler
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Recrutement en coursPhase 3
- University of Texas Health Center at Tyler, Tyler
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Recrutement en coursPhase 1
- Texas Oncology, P.A. - Oncology, Tyler
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Recrutement en coursPhase 1
- University of Texas at Tyler, Tyler
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Recrutement en coursPhase 1/2
- Texas Oncology - Northeast, Tyler
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Recrutement en coursPhase 1/2
- Texas Oncology - Northeast TX, Tyler
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Recrutement en coursPhase 1/2
- The University of Texas Health Science Center at Tyler, Tyler
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Recrutement en coursPhase 1
- UT Health East Texas HOPE Cancer Center, Tyler
- UT Health East Texas Hope Cancer Center, Tyler
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Recrutement en coursPhase 1
- Texas Oncology - Tyler, Tyler
Essais pour Cancer du poumon non à petites cellules dans d'autres villes
- Houston, TX145 études
- New York City, NY120 études
- Arlington, VA104 études
- Nashville, TN97 études
- Boston, MA90 études
- Los Angeles, CA87 études
- St. Louis, MO73 études
- Chicago, IL61 études
- Baltimore, MD60 études
- San Antonio, TX59 études
- Columbus, OH56 études
- Washington, DC55 études
Autres études à Tyler
- Maladie de Crohn16 études
- Colite ulcéreuse14 études
- Cancer colorectal8 études
- Insuffisance cardiaque8 études
- Cancer (tous types)7 études
- Cancer de l'ovaire7 études
- Cancer de l'endomètre6 études
- Carcinome épidermoïde de la tête et du cou6 études
- Cancer du sein6 études
- Cancer métastatique5 études
- Maladie inflammatoire chronique de l'intestin5 études
- Leucémie lymphocytaire chronique5 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.